Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Jewish General Hospital
Sponsor:
Collaborators:
Quebec Clinical Research Organization in Cancer
Novartis
Hoffmann-La Roche
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT01238692
First received: November 10, 2010
Last updated: January 17, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)